Vaxart Jumps 38% After Positive Norovirus Trial [Yahoo! Finance]
Vaxart, Inc. (VXRT)
Last vaxart, inc. earnings: 3/19 04:01 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
vaccine pill, with antibody responses up 141% against GI.1 and 94% against GII.4 strains versus first-gen candidates. Warning! GuruFocus has detected 5 Warning Signs with VXRT. In the trial, healthy volunteers received multiple dose levels of the improved vaccine construct, which elicited robust blockade antibodies correlated with protection in norovirus challenge studies. All dose cohorts showed strong immunogenicity, and no serious adverse events were reported, underscoring the vaccine's safety and tolerability profile. These results mark a clear advancement over Vaxart's initial oral vaccine platform, addressing a major unmet need given norovirus's status as the leading cause of acute gastroenteritis worldwide. Looking ahead, Vaxart plans to kick off a Phase 2b safety and immunogenicity study in H2 2025 and will engage the U.S. Food and Drug Administration in a Type B meeting to review the data package. Subject to regulatory feedback, the company aims to launch a Phase 3
Show less
Read more
Impact Snapshot
Event Time:
VXRT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VXRT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VXRT alerts
High impacting Vaxart, Inc. news events
Weekly update
A roundup of the hottest topics
VXRT
News
- Vaxart, Inc. (VXRT) Shareholder/Analyst Call Transcript [Seeking Alpha]Seeking Alpha
- Vaxart, Inc. (VXRT) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Vaxart Q3 2025 Earnings Preview [Seeking Alpha]Seeking Alpha
- Vaxart to Host Upcoming Conference CallsGlobeNewswire
- Vaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025GlobeNewswire
VXRT
Earnings
- 11/13/25 - Beat
VXRT
Sec Filings
- 12/8/25 - Form 4
- 12/8/25 - Form 144
- 12/5/25 - Form 4
- VXRT's page on the SEC website